TY - JOUR T1 - Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs JF - medRxiv DO - 10.1101/2020.04.21.20066761 SP - 2020.04.21.20066761 AU - Veronique Michaud AU - Pamela Dow AU - Sweilem B. Al Rihani AU - Malavika Deodhar AU - Meghan Arwood AU - Brian Cicali AU - Jacques Turgeon Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/02/2020.04.21.20066761.abstract N2 - The risk-benefit ratio associated with the use of repurposed drugs to treat 2019 SARS-CoV-2 related infectious disease (COVID-19) is complicated since benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced Long QT Syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared to 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.Competing Interest StatementVeronique Michaud, Pamela Dow, Sweilem Al Rihani, Malavika Deodhar, Meghan Arwood, and Jacques Turgeon are all employees of Tabula Rasa HealthCare. Jacques Turgeon and Veronique Michaud are stock holders of Tabula Rasa HealthCare. Jacques Turgeon and Veronique Michaud have patents broadly related to the content of this paper. Veronique Michaud and Jacques Turgeon are faculty members at the Universite de Montreal. Brian Cicali is a previous employee of Tabula Rasa HealthCare, and is paid independently by TRHC for work outside of this paper.Funding StatementThis research was made possible by funding from Tabula Rasa HealthCare.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials. https://www.trhc.spprdi.com/covid19/home ER -